Literature DB >> 20947049

CMR predictors of mitral regurgitation in mitral valve prolapse.

Francesca N Delling1, Lih Lisa Kang, Susan B Yeon, Kraig V Kissinger, Beth Goddu, Warren J Manning, Yuchi Han.   

Abstract

OBJECTIVES: We sought to assess the correlation between mitral valve characteristics and severity of mitral regurgitation (MR) in subjects with mitral valve prolapse (MVP) undergoing cardiac magnetic resonance (CMR) imaging.
BACKGROUND: Compared with extensive echocardiographic studies, CMR predictors of MVP-related MR are unknown. The severity of MR at the time of diagnosis has prognostic implication for patients; therefore, the identification of determinants of MR and its progression may be important for risk stratification, follow-up recommendations, and surgical decision making.
METHODS: Seventy-one MVP patients (age 54 ± 11 years, 58% males, left ventricular [LV] ejection fraction 65 ± 5%) underwent cine CMR to assess annular dimensions, maximum systolic anterior and posterior leaflet displacement, papillary muscle (PM) distance to coaptation point and prolapsed leaflets, as well as diastolic anterior and posterior leaflet thickness and length, and LV volumes and mass. Velocity-encoded CMR was used to obtain aortic outflow and to quantify MR volume.
RESULTS: Using multiple linear regression analysis including all variables, LV mass (p < 0.001), anterior leaflet length (p = 0.006), and posterior displacement (p = 0.01) were the best determinants of MR volume with a model-adjusted R(2) = 0.6. When the analysis was restricted to valvular characteristics, MR volume correlated with anterior mitral leaflet length (p < 0.001), posterior mitral leaflet displacement (p = 0.003), posterior leaflet thickness (p = 0.008), and the presence of flail (p = 0.005) with a model-adjusted R(2) = 0.5. We also demonstrated acceptable intraobserver and interobserver variability in these measurements.
CONCLUSIONS: Anterior leaflet length, posterior leaflet displacement, posterior leaflet thickness, and the presence of flail are the best CMR valvular determinants of MVP-related MR. The acceptable intraobserver and interobserver variability of our measurements confirms the role of CMR as an imaging modality for assessment of MVP patients with significant MR.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20947049     DOI: 10.1016/j.jcmg.2010.06.016

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  12 in total

1.  Dynamic and quantitative evaluation of degenerative mitral valve disease: a dedicated framework based on cardiac magnetic resonance imaging.

Authors:  Francesco Sturla; Francesco Onorati; Giovanni Puppini; Omar A Pappalardo; Matteo Selmi; Emiliano Votta; Giuseppe Faggian; Alberto Redaelli
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 2.  Mitral Valve Prolapse: Multimodality Imaging and Genetic Insights.

Authors:  Purvi Parwani; Jean-Francois Avierinos; Robert A Levine; Francesca N Delling
Journal:  Prog Cardiovasc Dis       Date:  2017-11-06       Impact factor: 8.194

Review 3.  Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis.

Authors:  Francesca N Delling; Ramachandran S Vasan
Journal:  Circulation       Date:  2014-05-27       Impact factor: 29.690

Review 4.  Multimodality imaging assessment of mitral valve anatomy in planning for mitral valve repair in secondary mitral regurgitation.

Authors:  Romain Capoulade; Nicolas Piriou; Jean-Michel Serfaty; Thierry Le Tourneau
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 5.  Utility of cardiac magnetic resonance for evaluation of mitral regurgitation prior to mitral valve surgery.

Authors:  Neil K Mehta; Jiwon Kim; Jonathan Y Siden; Sara Rodriguez-Diego; Javid Alakbarli; Antonino Di Franco; Jonathan W Weinsaft
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

6.  Malignant Mitral Valve Prolapse: Risk and Prevention of Sudden Cardiac Death.

Authors:  Yasufumi Nagata; Philippe B Bertrand; Robert A Levine
Journal:  Curr Treat Options Cardiovasc Med       Date:  2022-03-22

Review 7.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the Use of Cardiac Magnetic Resonance in Pediatric Congenital and Acquired Heart Disease: Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  Circ Cardiovasc Imaging       Date:  2022-06-21       Impact factor: 8.589

Review 8.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the use of cardiovascular magnetic resonance in pediatric congenital and acquired heart disease : Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-21       Impact factor: 6.903

9.  Diffuse myocardial fibrosis in patients with mitral valve prolapse and ventricular arrhythmia.

Authors:  An H Bui; Sébastien Roujol; Murilo Foppa; Kraig V Kissinger; Beth Goddu; Thomas H Hauser; Peter J Zimetbaum; Long H Ngo; Warren J Manning; Reza Nezafat; Francesca N Delling
Journal:  Heart       Date:  2016-08-11       Impact factor: 5.994

10.  Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy.

Authors:  Mika Tarkiainen; Petri Sipola; Mikko Jalanko; Tiina Heliö; Mika Laine; Vesa Järvinen; Kaisu Häyrinen; Kirsi Lauerma; Johanna Kuusisto
Journal:  J Cardiovasc Magn Reson       Date:  2016-06-04       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.